Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng J-H, et al. Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with human immunodeficiency virus infections. Clin Infect Dis. 2019;68(8):1335–42.

Article  CAS  PubMed  Google Scholar 

Morrow M, Mawhinney S, Coyle RP, Coleman SS, Gardner EM, Zheng J-H, et al. Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV. J Infect Dis. 2019;220(4):635–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012. https://doi.org/10.1097/COH.0b013e32834f5cf2.

Article  PubMed  PubMed Central  Google Scholar 

Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: the role of adherence in the late HAART era. Antivir Ther. 2012;17(5):785–92.

Article  CAS  PubMed  Google Scholar 

Moosa A, Gengiah TN, Lewis L, Naidoo K. Long-term adherence to antiretroviral therapy in a South African adult patient cohort: a retrospective study. BMC Infect Dis. 2019;19(1):775.

Article  PubMed  PubMed Central  Google Scholar 

Jennings L, Robbins RN, Nguyen N, Ferraris C, Leu C-S, Dolezal C, et al. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. AIDS. 2022;36(7):933–40.

Article  CAS  PubMed  Google Scholar 

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60(11):6692–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ, Gardner EM, Macatangay BJC, et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis. 2016;63(12):1661–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Musinguzi N, Jose C-M, Morrow M, Byakwaga H, Mawhinney S, Burdo TH, et al. Antiretroviral therapy adherence interruptions are associated with systemic inflammation among Ugandans who achieved viral suppression. J Acquir Immune Defic Syndrom. 2019;82(4):386.

Article  CAS  Google Scholar 

Castillo-Mancilla JR, Musinguzi N, Asiimwe S, Siedner MJ, Orrell C, Bangsberg DR, et al. High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa. HIV Med. 2022;23(5):465–73.

Article  CAS  PubMed  Google Scholar 

Smith R, Villanueva G, Probyn K, Sguassero Y, Ford N, Orrell C, et al. Accuracy of measures for antiretroviral adherence in people living with HIV. Cochrane Database of Syst Rev. 2022;7:7.

Google Scholar 

Haberer JE, Kahane J, Kigozi I, Emenyonu N, Hunt P, Martin J, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.

Article  PubMed  PubMed Central  Google Scholar 

Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.

Article  PubMed  PubMed Central  Google Scholar 

Orrell C, Cohen K, Mauff K, Bangsberg DR, Maartens G, Wood R. A randomized controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015;70(5):495–502.

Article  PubMed  Google Scholar 

Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15(1):49–59.

Article  PubMed  PubMed Central  Google Scholar 

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710-e1717.

Article  PubMed  Google Scholar 

Castillo-Mancilla JR, Zheng J-H, Rower JE, Meditz A, Gardner EM, Predhomme J, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013;29(2):384–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Republic of South Africa, National Department of Health. 2023 ART Clinical Guidelines for the management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates. Pages 7-20. Published 24 April 2023.

Mansky LMPD, Gajary LC. Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. J Virol. 2002. https://doi.org/10.1128/jvi.76.18.9253-9259.2002.

Article  PubMed  PubMed Central  Google Scholar 

Jennings L, Kellermann T, Spinelli M, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Drug resistance, rather than low tenofovir levels in blood or Urine, is associated with tenofovir, emtricitabine, and efavirenz failure in resource-limited settings. AIDS Res Hum Retroviruses. 2022;38(6):455–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castillo-Mancilla JR, Edwards JA, Brijkumar J, Moosa MY, Zhao Y, Ofotokun I, et al. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case–control cohort study. J Int AIDS Soc. 2021;24(12): e25849.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17(4):301–14.

Article  PubMed  PubMed Central  Google Scholar 

Kristofich M, Anderson PL, Castillo-Mancilla JR. Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatch. Ther Adv Infect Dis. 2021;8:204993612110105.

Google Scholar 

Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.

Article  CAS  PubMed  Google Scholar 

Reinius M, Wettergren L, Wiklander M, Svedhem V, Ekström AM, Eriksson LE. Development of a 12-item short version of the HIV stigma scale. Health Quality Life Outcomes. 2017;15:1–9.

Article  Google Scholar 

Breuer E, Stoloff K, Myer L, Seedat S, Stein DJ, Joska JA. The validity of the substance abuse and mental illness symptom screener (SAMISS) in people living with HIV/AIDS in primary HIV care in cape town. South Africa AIDS Behav. 2014;18(6):1133–41.

Article  PubMed  Google Scholar 

Yager JL, Coyle RP, Coleman SS, Ellison L, Zheng J-H, Bushman L, et al. Moderately high tenofovir diphosphate in dried blood spots indicates drug resistance in viremic persons living with HIV. J Int Assoc Provid AIDS Care. 2019;18:232595821988845.

Article  Google Scholar 

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, et al. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018;73(6):1665–71.

Article  CAS  PubMed  Google Scholar 

Deschamps AE, Wijngaerden EV, Denhaerynck K, Geest SD, Vandamme A-M. Use of electronic monitoring induces a 40-day intervention effect in HIV patients. JAIDS J Acquir Immune Defic Syndr. 2006;43(2):247–8.

Article  PubMed  Google Scholar 

Lm M. HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updates. 2002;5(6):219–23.

Article  Google Scholar 

Peinado Cortes LM, Zurakowski R. editor Resistance evolution in HIV—modeling when to intervene. Proc Am Control Conf. 2012. https://doi.org/10.1109/ACC.2012.6315693.

Article  Google Scholar